Eton Pharmaceuticals (ETON) Income from Continuing Operations (2018 - 2025)

Eton Pharmaceuticals has disclosed Income from Continuing Operations across 8 years of filings, most recently posting 1483000.0 for Q4 2025.

• Income from Continuing Operations for Q4 2025 came in at 1483000.0, up 347.99% year-over-year; the trailing twelve-month figure through Dec 2025 was 4601000.0 (down 20.35% YoY), and the FY2025 annual result was 4601000.0, down 20.35% from the prior year.
• Income from Continuing Operations came in at 1483000.0 for Q4 2025 at Eton Pharmaceuticals, up from 1927000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 5116000.0 in Q1 2021 to a low of 6094000.0 in Q3 2021.
• The 5-year median for Income from Continuing Operations is 1565000.0 (2022), against an average of 1016800.0.
• Across the five-year window, Income from Continuing Operations jumped 392.62% in 2023 and tumbled 407.34% in 2025, its largest moves.
• Eton Pharmaceuticals' Income from Continuing Operations stood at 1039000.0 in 2021, then declined by 12.22% to 912000.0 in 2022, then tumbled by 347.37% to 2256000.0 in 2023, then soared by 73.49% to 598000.0 in 2024, then jumped by 347.99% to 1483000.0 in 2025.
• The last three Income from Continuing Operations figures came in at 1483000.0 (Q4 2025), 1927000.0 (Q3 2025), and 2585000.0 (Q2 2025), per Business Quant data.